📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Antifungal Treatment Companies

Anti-fungal treatment companies are involved in the research, development, and commercialization of pharmaceuticals, therapies, and medical products aimed at treating fungal infections. These companies play a vital role in addressing fungal diseases and supporting the health of affected individuals.

Antifungal Treatment  Key CompaniesDisclaimer: List of key companies in no particular orderLatest Anti-fungal treatment Companies Update

  • Aug 2023: Gilead Sciences announced that just one month after the firm canceled a late-stage study due to effectiveness concerns, the US health government put a clinical hold on tests of its blood cancer treatment. When the corporation acquired Forty-Seven Inc. for $4.9 billion in March 2020, it acquired access to the medication magrolimab. According to the business, the U.S. Food and Drug Administration (FDA) has stopped screening and enrolling new study participants. However, patients who are currently enrolled in studies may still get treatment. According to the business, studies on magrolimab in solid tumors will proceed unaffected by the FDA's action. The medicine was being studied by the business to treat individuals who have a greater chance of myelodysplastic syndromes, a rare category of illnesses causing bone marrow loss, in conjunction with azacitidine chemotherapy.

  • Oct 2023: Even after worries about potential liver damage surfaced, Merck KGaA stated that its experimental multiple sclerosis treatment can still be a "blockbuster," an industry word for yearly sales exceeding $1 billion. As the front-runner in the quest to acquire permission for a more focused kind of MS medication, Merck's stock price fell in April after the US regulators announced that they were stopping the enrollment of new patients in a trial evaluating the medication evobrutinib. The afflicted two patients did not exhibit any symptoms and did not require medical attention, the business maintained at the time, even though the U.S. Food and Drug Administration had referenced laboratory evidence suggesting drug-induced liver impairment.

List of Anti-fungal treatment Key companies in the market

  • Pfizer Inc. (US)

  • Astellas Pharma Ltd. (Japan)

  • Novartis International AG (Switzerland)

  • Sanofi S.A. (France)

  • Merck KGaA (Germany)

  • Bayer AG (Germany)

  • Abbott Laboratories (US)

  • Janssen Pharmaceuticals (US)

  • Gilead Sciences, Inc. (US)

  • Cipla Inc. (India)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.